GT Biopharma registers 13.5M shares: what it means for GT Biopharma stock

Published on 10/14/2026 at 04:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The October 9 filing lists 2,061,052 shares outstanding. Its dilution risk shapes GT Biopharma stock through 2026 and beyond.

Financing and registration timeline

The October 9 filing registered up to 13,502,835 common shares for resale.
GT Biopharma reported 2,061,052 common shares outstanding as of October 9, 2026.
RankedStocks lists November 13, 2026 as the next earnings date.

GTBP, US36254L4077, Illustration mit AI erstellt.

GT Biopharma (ISIN US36254L4077) registered up to 13,502,835 common shares for resale in a preliminary filing dated October 9, 2026. The filing also listed 2,061,052 common shares outstanding, making potential dilution the clearest issue for GT Biopharma stock. StockTitan reported that the registration covers shares held by selling stockholders and that the company would not receive proceeds from their resales.

What the resale filing means

The S-1 does not itself authorize an immediate sale. It describes a proposed resale of shares tied to preferred-stock conversions, warrants and preferred-stock dividends, while the registration statement remains subject to effectiveness.

The filing gives the capital structure a concrete scale. It lists 6,716,931 Series M conversion shares and 6,716,931 Series M warrant shares, alongside smaller Series L and dividend-related amounts. It also states that the company had received USD 9.71 million in gross proceeds from Series L Greenshoe Rights exercised to date.

Three dated capital events

On September 8, 2026, a 1-for-25 reverse stock split reduced the common share count from 45,109,497 pre-split shares to 1,804,379 post-split shares, according to StockTitan.

On September 14, 2026, GT Biopharma entered a private placement with an aggregate purchase price of USD 7.75 million, according to StockTitan. The September financing and the October resale registration are connected by the preferred stock and warrant instruments described in the filing.

On September 15, 2026, GT Biopharma announced a potential multiple-myeloma indication for GTB-5550 after FDA investigational new drug clearance, according to the company's press release. The program is part of the company's TriKE immuno-oncology platform.

What comes next for GTBP

GT Biopharma's investor-relations page identifies Nasdaq as the listing venue for GTBP and shows the latest financial-results period as the second quarter of 2026, ended June 30, 2026. A separate earnings calendar lists November 13, 2026 as the next earnings date, according to RankedStocks.

The last quoted primary-market price was USD 6.50 on Nasdaq on October 13, 2026 at 4:00 p.m. ET. For investors, the key comparison is between the 2,061,052 shares outstanding and the 13,502,835 shares registered for resale, although the latter figure includes securities that may require conversion or exercise before issuance.

Capital structure sets the near-term theme

The further course of corporate developments will depend on the effectiveness of the registration statement, warrant activity and the company's clinical progress. The capital structure now carries more immediate numerical weight than the pipeline narrative alone.

Market context: Market report Nasdaq Composite.